Experiment 68336
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | ORAL |
| Organism | Empty organism |
| Citation | CRESPO,N: ILLNAIT,J: MAS,R: FERNANDEZ,L: FERNANDEZ,J: CASTANO,G:. (1999). COMPARATIVE STUDY OF THE EFFICACY AND TOLERABILITY OF POLICOSANOL AND LOVASTATIN IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS.. 19(4) |
| Amount utilized | |
| Compound isolated | |
| Disease | THIS RANDOMIZED, DOUBLE-BLIND STUDY WAS UNDERTAKEN TO COMPARE THE EFFICACY AND TOLERABILITY OF POLICOSANOL (10 MG/DAY) AAND LOVASTATIN (20 MG/DAY) IN PATIENTS WITH HYPERCHOLESTEROLEMIA AND NONINSULIN DEPENDENT DIABETES MELLITUS. BOTH GROUPS WERE SIMILAR AT RANDOMIZATION. POLICOSANOL SIGNIFICANTLY (P<0.001) LOWERED LOW-DENSITY LIPOPROTEIN (LDL)-CHOLESTEROL (20.4%), TOTAL CHOLESTEROL (14.2%) AND THE RATIO OF LDL-CHOLESTEROL TO HIGH-DENSITY LIPOPROTEIN (HDL)-CHOLOESTEROL (23.7%). POLICOSANOL, BUT NOT LOVASTATIN, SIGNIFICANTLY INCREASED (P<0.01) LEVELS OF HDL-CHOLESTEROL (7.5%). COMPARISON BETWEEN GROUPS SHOWED THAT CHANGES IN HDL-CHOLESTEROL INDUCED BY POLICOSANOL WERE SIGNIFICANTLY GREATER (P<0.01) THAN THOSE INDUCED BY LOVASTATIN. BOTH TREATMENT WERE SAFE AND WELL TOLERATED. POLICOSANOL ADMINISTERED AT 10 MG/DAY PRODUCES MORE ADVANTAGEOUS CHANGES IN HDL-CHOLESTEROL AND HAS A BETTER SAFETY AND TOLERABILITY PROFILE THAN LOVASTAIN 20 MG/DAY. |
| Dose amount | 10.0Q MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |